glp-1 fda approved for pcos Women with a common hormonal disorder have few good treatment options. Could drugs help? GLP-1 Pipeline Update: May 2025
Description
A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes
Electroacupuncture demonstrated similar findings, relieving pain hypersensitivity in rats with spared nerve injury [32]
Still, many insurance companies treat them as lifestyle drugs and deny claims
A conversation with your prescriber about an FDA-approved alternative is worth having sooner rather than later
Older adults and patients with diabetes complications warrant proactive medication adjustment strategies
